http://orcid.org/0000-0002-1713-0923
Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Ioanna Papakitsou, George Vougiouklakis, Moses S Elisaf & Theodosios D Filippatos. (2019) Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes. Clinical Pharmacology: Advances and Applications 11, pages 133-143.
Read now
Read now
André J Scheen. (2019) An update on the safety of SGLT2 inhibitors. Expert Opinion on Drug Safety 18:4, pages 295-311.
Read now
Read now
Theodosios D. Filippatos, Angelos Liontos, Ioanna Papakitsou & Moses S. Elisaf. (2019) SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses. Postgraduate Medicine 131:2, pages 82-88.
Read now
Read now
Brian M Inouye, Francis M Hughes$suffix/text()$suffix/text(), Huixia Jin, Robin Lütolf, Kunal C Potnis, Jonathan C Routh, Douglas C Rouse, Wen-Chi Foo & J Todd Purves. (2018) Diabetic bladder dysfunction is associated with bladder inflammation triggered through hyperglycemia, not polyuria. Research and Reports in Urology 10, pages 219-225.
Read now
Read now
Sempastian Filippas-Ntekouan, Vasilios Tsimihodimos, Theodosios Filippatos, Theodora Dimitriou & Moses Elisaf. (2018) SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids. Expert Opinion on Drug Metabolism & Toxicology 14:11, pages 1113-1121.
Read now
Read now
Jingbo Hu, Aiping Deng & Yufen Zhao. (2018) Ertugliflozin as a monotherapy for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 19:16, pages 1841-1847.
Read now
Read now
Articles from other publishers (40)
Jinmi Lee, Seok-Woo Hong, Min-Jeong Kim, Yu-Mi Lim, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee & Won-Young Lee. (2024) Inhibition of Sodium-Glucose Cotransporter-2 during Serum Deprivation Increases Hepatic Gluconeogenesis via the AMPK/AKT/FOXO Signaling Pathway. Endocrinology and Metabolism 39:1, pages 98-108.
Crossref
Crossref
Laura Scott, Lan-Linh Truong, Robyn L. Houlden & Don Thiwanka Wijeratne. (2024) Screening and Management Recommendations for Type 2 Diabetes in Women With Breast Cancer. Canadian Journal of Diabetes 48:1, pages 66-72.
Crossref
Crossref
Sepideh Parchami Ghazaee, Viktor Tumanov, Natalia Voloshyna, Kateryna Marchenko-Tolsta & Murtaza Hameed. (2023) A Review of the Novel Antidiabetic Medications: Efficacy, Safety and
Innovation. New Emirates Medical Journal 4:1.
Crossref
Crossref
Jacob E. Pruett, Damian G. Romero & Licy L. Yanes Cardozo. (2023) Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors. Frontiers in Endocrinology 14.
Crossref
Crossref
Mohammed Moutaz Nakhal, Salahdein Aburuz, Bassem Sadek & Amal Akour. (2022) Repurposing SGLT2 Inhibitors for Neurological Disorders: A Focus on the Autism Spectrum Disorder. Molecules 27:21, pages 7174.
Crossref
Crossref
Wajd Alkabbani, Arsène Zongo, Jasjeet K. Minhas‐Sandhu, Dean T. Eurich, Baiju R. Shah, Mhd. Wasem Alsabbagh & John‐Michael Gamble. (2022) Five comparative cohorts to assess the risk of genital tract infections associated with sodium‐glucose cotransporter‐2 inhibitors initiation in type 2 diabetes mellitus. Diabetic Medicine 39:8.
Crossref
Crossref
Giovanna B. Carpentieri, Sandra E. A. B. Gonçalves, Mayra Z. Casagrande, Walid M. Mourad, Lara G. C. Pinto & Maria Teresa Zanella. (2022) SGLT2 Inhibition with Empagliflozin as a Possible Therapeutic Option for Postprandial Hypoglycemia After Bariatric Surgery. Obesity Surgery 32:8, pages 2664-2671.
Crossref
Crossref
Samuel Dagogo‐Jack, Christopher P. Cannon, David Z. I. Cherney, Francesco Cosentino, Jie Liu, Annpey Pong, Ira Gantz, Robert Frederich, James P. Mancuso & Richard E. Pratley. (2022)
Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose‐lowering agent: An analysis from
VERTIS CV
. Diabetes, Obesity and Metabolism 24:7, pages 1245-1254.
Crossref
Crossref
Brooks Richardson, Mohammad Qasim Khan, Sara A Brown, Kymberly D Watt & Manhal Izzy. (2021) Personalizing Diabetes Management in Liver Transplant Recipients: The New Era for Optimizing Risk Management. Hepatology Communications 6:6, pages 1250-1261.
Crossref
Crossref
Sheng Chen. (2022) circ_000166/miR-296 Aggravates the Process of Diabetic Renal Fibrosis by Regulating the SGLT2 Signaling Pathway in Renal Tubular Epithelial Cells. Disease Markers 2022, pages 1-10.
Crossref
Crossref
Muhammad Akbar Baig & Joshua Nogar. (2022) Euglycemia despite a sodium glucose co-transporter 2 inhibitor overdose. World Journal of Emergency Medicine 13:2, pages 147.
Crossref
Crossref
György Rokszin, Zoltán Kiss, Gábor Sütő, Péter Kempler, György Jermendy, Ibolya Fábián, Zoltán Szekanecz, Gyula Poór, István Wittmann & Gergő Attila Molnár. (2021) Sodium-Glucose Co-Transporter 2 Inhibitors May Change the Development of Urinary Tract and Hematological Malignancies as Compared With Dipeptidyl Peptidase-4 Inhibitors: Data of the Post-Hoc Analysis of a Nationwide Study. Frontiers in Oncology 11.
Crossref
Crossref
Mohit Chandrashekar, Stuart Philip, Alexander Nesbitt, Andre Joshi & Marlon Perera. (2021) Sodium glucose‐linked transport protein 2 inhibitors: An overview of genitourinary and perioperative implications. International Journal of Urology 28:10, pages 984-990.
Crossref
Crossref
Kai-Fan Tsai, Yung-Lung Chen, Terry Ting-Yu Chiou, Tian-Huei Chu, Lung-Chih Li, Hwee-Yeong Ng, Wen-Chin Lee & Chien-Te Lee. (2021) Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases. Antioxidants 10:8, pages 1166.
Crossref
Crossref
Zay M Htet & Mahzuz Karim. (2021) Sodium-glucose co-transporter 2 inhibitors: game changers when handled with care?. Journal of the Royal Society of Medicine 114:7, pages 351-358.
Crossref
Crossref
Ildiko Lingvay, Michelle Greenberg, Silvina Gallo, Harry Shi, Jie Liu & Ira Gantz. (2021)
Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A
VERTIS CV
substudy
. Diabetes, Obesity and Metabolism 23:7, pages 1640-1651.
Crossref
Crossref
Hakan KORKMAZ. (2021) COVID-19 ve Diabetes Mellitus YönetimiCOVID-19 and Diabetes Mellitus Management. SDÜ Tıp Fakültesi Dergisi 28:COVİD-19 ÖZEL SAYI, pages 171-175.
Crossref
Crossref
I. Agra Montava, M. Seres Roig & V. Jodar Manzaneda. (2021) Cetoacidosis diabética euglucémica, ¿más iatrogenia?. Medicina de Familia. SEMERGEN 47:2, pages 135-136.
Crossref
Crossref
Lihua Ni, Cheng Yuan, Guopeng Chen, Changjiang Zhang & Xiaoyan Wu. (2020) SGLT2i: beyond the glucose-lowering effect. Cardiovascular Diabetology 19:1.
Crossref
Crossref
Morten Hasselstrøm Jensen, Claus Dethlefsen, Ole Hejlesen & Peter Vestergaard. (2019) Association of severe hypoglycemia with mortality for people with diabetes mellitus during a 20-year follow-up in Denmark: a cohort study. Acta Diabetologica 57:5, pages 549-558.
Crossref
Crossref
Canan ERSOY. (2020) SGLT 2 inhibitors: Antidiabetic agents with promising effects beyond glucose control. Turkish Journal of Internal Medicine 2:1, pages 1-4.
Crossref
Crossref
In Hee Lee & Dong Jik Ahn. (2020) Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus. Medicine 99:21, pages e20228.
Crossref
Crossref
Habib Yaribeygi, Thozhukat Sathyapalan, Mina Maleki, Tannaz Jamialahmadi & Amirhossein Sahebkar. (2020) Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: A mechanistic review. Life Sciences 240, pages 117090.
Crossref
Crossref
S. S. Bolevich, P. F. Litvitsky, V. Jakovljevic & S. B. Bolevich. (2019) Long-term use of dipeptyl peptidase-4 inhibitors suppresses systemic oxidative stress in rats with type 2 diabetes. Sechenov Medical Journal 10:4, pages 21-30.
Crossref
Crossref
Haiyan Fu, Silvia Liu, Sheldon I. Bastacky, Xiaojie Wang, Xiao-Jun Tian & Dong Zhou. (2019) Diabetic kidney diseases revisited: A new perspective for a new era. Molecular Metabolism 30, pages 250-263.
Crossref
Crossref
Janet B. McGill & Savitha Subramanian. (2019) Safety of Sodium-Glucose Co-Transporter 2 Inhibitors. The American Journal of Cardiology 124, pages S45-S52.
Crossref
Crossref
Atsunori Kashiwagi, Marina V. Shestakova, Yuichiro Ito, Masahiro Noguchi, Wim Wilpshaar, Satoshi Yoshida & John P. H. Wilding. (2019) Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials. Diabetes Therapy 10:6, pages 2201-2217.
Crossref
Crossref
Kenan Çadırcı, Özlem Özdemir Tozlu & Hasan Türkez. (2019) The in vitro cytotoxicity, genotoxicity and oxidative damage potential of dapagliflozin, on cultured human blood cells. Turkish Journal of Biochemistry 44:5, pages 692-698.
Crossref
Crossref
Lev M. Berstein. (2019) Is cancer incidence modified by SGLT2 inhibitors?. Diabetes mellitus 22:4, pages 399-402.
Crossref
Crossref
Priyanka A. Shah, Pranav S. Shrivastav, Vinay Sharma & Manish S. Yadav. (2019) Challenges in simultaneous extraction and chromatographic separation of metformin and three SGLT-2 inhibitors in human plasma using LC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis 175, pages 112790.
Crossref
Crossref
Janet B. McGill & Savitha Subramanian. (2019) Safety of Sodium-Glucose Co-Transporter 2 Inhibitors. The American Journal of Medicine 132:10, pages S49-S57.e5.
Crossref
Crossref
Amr Dokmak, Mohammad Almeqdadi, Hirsh Trivedi & Sandeep Krishnan. (2019) Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease. World Journal of Hepatology 11:7, pages 562-573.
Crossref
Crossref
Md. Mahbubur Rahman Bhuiyan & Anawara Begum. (2019) Promise, peril, and possible new treatment options incurred by sodium glucose co-transporter 2 (SGLT2) inhibitors: A precise review up to 2018. Obesity Medicine 14, pages 100099.
Crossref
Crossref
Patricia Keresztes & Annette Peacock-Johnson. (2019) CE: Type 2 Diabetes: A Pharmacologic Update. AJN, American Journal of Nursing 119:3, pages 32-40.
Crossref
Crossref
Manash P Baruah & Sanjay Kalra. (2019) Comparative Efficacy and Safety Among Sodium-glucose Cotransporter-2 Inhibitors in Type 2 Diabetes – Results from a Retrospective Single-centre Study. European Endocrinology 15:2, pages 113.
Crossref
Crossref
Emanuel Raschi, Elisabetta Poluzzi, Gian Paolo Fadini, Giulio Marchesini & Fabrizio De Ponti. (2018) Observational research on sodium glucose co‐transporter‐2 inhibitors: A real breakthrough?. Diabetes, Obesity and Metabolism 20:12, pages 2711-2723.
Crossref
Crossref
V. Tsimihodimos, T.D. Filippatos & M.S. Elisaf. (2018) SGLT2 inhibitors and the kidney: Effects and mechanisms. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 12:6, pages 1117-1123.
Crossref
Crossref
André J. Scheen. (2018) GLP-1 receptor agonists and cardiovascular protection: A class effect or not?. Diabetes & Metabolism 44:3, pages 193-196.
Crossref
Crossref
Kanwal Rehman, Kiran Saeed, Syeda Mehak Munawar & Muhammad Sajid Hamid Akash. (2018) Resveratrol regulates hyperglycemia-induced modulations in experimental diabetic animal model. Biomedicine & Pharmacotherapy 102, pages 140-146.
Crossref
Crossref
A.-J. Scheen. (2018) Place des inhibiteurs des SGLT2 dans le traitement du patient diabétique de type 2. Médecine des Maladies Métaboliques 12:1, pages 22-30.
Crossref
Crossref